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ABSTRACT
Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown 
to mediate immune evasion in various cancers, but their prognostic implications in 
patients with primary central nervous system lymphoma (PCNSL) are poorly 
understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who 
were treated homogenously with high-dose methotrexate-based chemotherapy, and 
evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 
expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-
L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under 
the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was 
high in 7.9%, 13.2%, and 42.1% patients, respectively. High PD-1, (P = 0.007) and 
Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were 
independently associated with inferior overall survival on multivariate analysis. High 
PD-1 also remained an independent prognostic factor for inferior progression-free 
survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate 
analysis. However, there were no differences in survival according to the expression 
levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that 
PD-1 may be considered a biomarker and potential therapeutic target in PCNSL.
INTRODUCTION
Primary central nervous system (CNS) lymphoma 
(PCNSL) is an extranodal non-Hodgkin lymphoma 
(NHL) confined to the CNS, mostly diffuse large B-cell 
lymphoma (DLBCL) [1]. Currently, the International 
Extranodal Lymphoma Study Group (IELSG) and 
Memorial Sloan Kettering Cancer Center (MSKCC) 
prognostic scoring systems are the best available 
clinical tools to risk-stratify patients with PCNSL [2, 
3]. However, these prognostic scores do not take into 
account underlying tumor biological factors, such as 
tumor microenvironment of PCNSL. Several biomarkers 
for PCNSL have been suggested, including multiple 
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myeloma oncogene 1/interferon regulatory factor 
4 (MUM1/IRF4), B-cell lymphoma-6 (BCL-6) and 
CD68, but their major limitation is that it is difficult to 
use those biomarkers as a potential therapeutic target 
[4–6]. Therefore, discovering a novel biomarker that 
supplements IELSG and MSKCC prognostic scoring 
system and that can be used as a therapeutic target is 
desperately needed to improve prognostication and 
survival of patients with PCNSL.
Tumor microenvironment per se is important for 
PCNSL development and progression as well as other 
malignancies [7]. This is also supported by the study that 
showed characteristic infiltration by tumor infiltrating 
lymphocytes in perivascular microenvironment of 
PCNSL, which was associated with survival [8]. Albeit 
the immunological role of T-cell infiltration in PCNSL is 
unclear, emerging data are suggesting that tumors have 
developed evasion mechanisms that exploit immune 
checkpoints to overcome antitumor immunity [9].
The immune checkpoint molecule programmed cell 
death 1 (PD-1) and its ligands PD-L1 and PD-L2 have 
been shown to play key roles in inhibiting T cell activity 
in the tumor microenvironment, not only in solid cancers 
but also in hematologic malignancies [10]. PD-1 and its 
ligands have been highlighted because their blockade 
showed outstanding clinical responses in advanced 
hematologic malignancies [11].
Importantly, PCNSL exhibited frequent 9p24.1/
PD-L1/PD-L2 copy number alterations [9] and even 
PD-1 blockade demonstrated clinical activity in relapsed/
refractory PCNSL [12], although only small number of 
patients were evaluated. Based on these findings, we 
sought to evaluate PD-1, PD-L1, and PD-L2 expressions 
in immunocompetent PCNSL patients at diagnosis, as well 
as their prognostic implication.
RESULTS
Patients’ characteristics
Baseline patient characteristics according to PD-1, 
PD-L1, and PD-L2 expression levels are summarized in 
Table 1. The median follow-up duration for all patients 
was 20.2 (range, 2.2–128.5) months, and the median 
follow-up duration for surviving patients was 31.9 (range, 
2.4–128.5) months. Serum Epstein-Barr virus (EBV) DNA 
was detected in 16 (21.1%) patients (median 9,200 [range 
1,944-88,000] copies/mL blood).
All the patients received high-dose-methotrexate 
(HD-MTX)-based chemotherapy as an initial treatment 
and there were no significant differences in survival 
according to the initial HD-MTX-based chemotherapy 
regimens patients received. Sixteen (21.1%) patients 
received consolidative upfront autologous stem-cell 
transplantation (ASCT) after a median of 4 cycles (range 
2–4) of HD-MTX-based chemotherapy. Ten (16.7%) 
patients received salvage ASCT. Busulfan plus thiotepa 
conditioning regimen was used for upfront or salvage 
ASCT. Twelve (15.8%) patients received consolidation 
whole-brain radiotherapy (WBRT, median 40.5 [range 
25.2–45.0] Gy), and 14 (18.4%) patients underwent 
salvage WBRT (median 41.4 [range 36.0–54.0] Gy).
Patients did not reach median Overall survival (OS), 
and the median progression-free survival (PFS) was 18.4 
months (95% CI, 9.9–26.8). The two-year OS and PFS 
rates were 76.3% and 45.4%, respectively.
Immunohistochemical PD-1, PD-L1 and PD-L2 
expression
Overall, the median PD-1 positive cells/high power 
field (HPF) was 0 (range, 0–240). Among 76 patients, 41 
(53.9%) patients did not show PD-1 positive cells/HPF. 
However, remaining 35 (46.1%) patients expressed at 
least one PD-1 positive cells/HPF. The median positive 
cells/HPF was 10 (range, 0–300) for PD-L1 and 70 (range, 
0–300) for PD-L2. Twenty-two (28.9%) and 12 (15.8%) 
patients did not express PD-L1 and PD-L2, respectively. 
Remaining 54 (71.1%) and 64 (84.2%) patients expressed 
at least one PD-L1 and PD-L2 positive cells/HPF, 
respectively. We stratified patients into high or low PD-
1, PD-L1, and PD-L2 expression groups according to the 
area under curve (AUC)-based cut-off values. Six (7.9%) 
patients were stratified into the high PD-1 expression 
group. Ten (13.2%) and 32 (42.1%) patients were stratified 
into the high PD-L1 and high PD-L2 expression groups, 
respectively. Representative immunohistochemical stains 
of PD-1 (Figure 1b), PD-L1 (Figure 1c), and PD-L2 
(Figure 1d) are shown in Figure 1 with unstained control 
(Figure 1a).
Prognostic factors for survival
On univariate analysis, age > 60 years and Eastern 
Cooperative Oncology Group (ECOG) performance status 
(PS) ≥ 2, MSKCC prognostic scoring, IELSG prognostic 
scoring, and high PD-1 expression level were associated 
with inferior OS. MSKCC prognostic scoring, patients 
who did not achieve complete response at initial interim 
response (non-CR1), patient who did not receive upfront 
ASCT, and high PD-1 level were associated with inferior 
PFS also in univariate analysis. On multivariate analysis, 
high PD-1 (hazard ratio (HR): 4.95, 95% confidence 
interval (CI): 1.54–15.86, P = 0.007) and MSKCC 
prognostic scoring (HR: 2.56, 95% CI: 1.17-5.64, P = 
0.019) were independently associated with inferior OS. 
High PD-1 also remained an independent prognostic factor 
for inferior PFS, (HR 2.73, 95% CI: 1.12-6.69, P = 0.028) 
as did MSKCC prognostic scoring (HR: 1.56, 95% CI: 
1.09-2.45, P = 0.041) on multivariate analysis. However, 
PD-L1 and PD-L2 expression levels were not prognostic 
in our cohort (Table 2).
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Survival according to the expression levels of  
PD-1, PD-L1, and PD-L2
Patients with high expression of PD-1 showed 
significantly shorter 2-year OS and PFS of 33.3% and 
0.0%, in comparison to 81.2% and 50.5% for those with 
low expression of PD-1 (P = 0.008 for OS; Figure 2a, and 
P = 0.037 for PFS; Figure 2b), respectively.
Regarding PD-1 ligands, there were no differences 
in survival according to the levels of PD-L1 and PD-
L2 expression (Figure 2c-2d for PD-L1 and Figure 2e-
2f for PD-L2, respectively). Two-year survival rates 
of patients according to the PD-1, PD-L1, and PD-L2 
expression status are provided in Table 3 and associations 
of PD-1, PD-L1, and PD-L2 expression levels with 
survival are summarized in Table 4.
Subgroup analysis of patients without upfront 
ASCT according to PD-1 expression level
As high PD-1 expression was independently 
associated with inferior survival in our whole patients, 
we performed subgroup analysis in patients who did not 
undergo upfront ASCT according to the level of PD-1 
Table 1: Baseline characteristics of all patients and subgroups according to the levels of PD-1, PD-L1, and PD-L2 ex
pression
Clinical features, 
n (%)
Entire cohort Subgroups
(n = 76)
PD-1
P
PD-L1
P
PD-L2
P
Low (n = 70) High (n = 6) Low (n = 66) High (n = 10) Low (n = 44) High (n = 32)
Median age, year 57 (33-79) 56 (33-79) 59 (34-68) 56 (33-79) 59 (34-64) 58 (36-79) 56 (33-74)
Age >60 30 (39.5) 28 (40.0) 2 (33.3) 0.556 28 (42.4) 2 (20.0) 0.158 27 (61.4) 19 (59.4) 0.524
Male gender 39 (51.3) 36 (51.4) 3 (50.0) 0.637 35 (53.0) 4 (40.0) 0.334 23 (52.3) 16 (50.0) 0.514
ECOG PS ≥2 35 (46.1) 34 (48.6) 1 (16.7) 0.209 29 (43.9) 6 (60.0) 0.271 17 (38.6) 18 (56.3) 0.099
Elevated serum 
LDH 34 (44.7) 33 (47.1) 1 (16.7) 0.216 29 (43.9) 5 (50.0) 0.489 20 (45.5) 14 (43.8) 0.535
Deep lesion 51 (67.1) 47 (67.1) 4 (66.7) 0.649 43 (65.2) 8 (80.0) 0.293 27 (61.4) 24 (75.0) 0.158
Elevated CSF 
protein 30/66 (39.4) 28/61 (40.0) 2/5 (33.3) 0.587 27/57 (40.9) 3/9 (30.0) 0.339 18/39 (40.9) 12/27 (37.5) 0.546
Positive serum 
EBV 16 (21.1) 14 (20.0) 2 (33.3) 0.371 14 (21.2) 2 (20.0) 0.648 11 (25.0) 5 (15.6) 0.242
Histology, 
DLBCL/PTCL 75(98.7)/1(1.3) 69(98.6)/1(1.4) 6(100.0)/0(0.0) 0.921 65(98.5)/1(1.5) 10(100.0)/0(0.0) 0.868 43(97.7)/1(2.3) 32(100.0)/0(0.0) 0.579
IELSG 0.257 0.507 0.097
 Low (0-1) 12 (15.8) 10 (14.3) 2 (33.3) 10 (15.2) 2 (20.0) 8 (18.2) 4 (12.5)
  Intermediate 
(2-3) 46 (60.5) 43 (61.4) 3 (50.0) 41 (62.1) 5 (50.0) 29 (65.9) 17 (53.1)
 High (4-5) 8 (10.5) 8 (11.4) 0 (0.0) 6 (9.1) 2 (20.0) 2 (4.5) 6 (18.8)
 Missing 10 (13.2) 9 (12.9) 1 (16.7) 9 (13.6) 1 (10.0) 5 (11.4) 5 (15.6)
MSKCC 0.180 0.433 0.208
 Low (0) 15 (19.7) 13 (18.6) 2 (33.3) 13 (19.7) 2 (20.0) 9 (20.5) 6 (18.8)
 Intermediate (1) 32 (42.1) 29 (41.4) 3 (50.0) 27 (40.9) 5 (50.0) 21 (47.7) 11 (34.4)
 High (2) 29 (38.2) 28 (40.0) 1 (16.7) 26 (39.4) 3 (30.0) 14 (31.8) 15 (46.9)
Initial treatment 
MVD/MVP 41(53.9)/35(46.1) 37(52.9)/33(47.1) 4(66.7)/2(33.3) 0.416 40(60.6)/26(39.4) 1(10.0)/9(90.0) 0.003 25(56.8)/19(43.2) 16(50.0)/16(50.0) 0.361
Non-CR1 37 (48.7) 34 (48.6) 3 (50.0) 0.389 31 (47.0) 6 (60.0) 0.562 22 (50.0) 15 (46.9) 0.380
Upfront ASCT 16 (21.1) 15 (21.4) 1 (16.7) 0.629 13 (19.7) 3 (30.0) 0.352 9 (20.5) 7 (21.9) 0.550
Salvage ASCT 10 (13.2) 8 (11.4) 2 (33.3) 0.176 9 (13.6) 1 (10.0) 0.609 7 (15.9) 3 (9.4) 0.318
Consolidation 
WBRT 12 (15.8) 8 (11.4) 4 (66.7) 0.657 5 (7.6) 7 (70.0) 0.495 7 (15.9) 5 (15.6) 0.384
Salvage WBRT 14 (18.4) 13 (18.6) 1 (16.7) 0.696 12 (18.2) 2 (20.0) 0.590 9 (20.5) 5 (15.6) 0.411
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; DLBCL, diffuse large 
B-cell lymphoma; PTCL, peripheral T-cell lymphoma; IELSG, International Extranodal Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; MVD, methotrexate, 
vincristine and dexamethasone; MVP, methotrexate, vincristine, procarbazine and dexamethasone; CR1, complete response after first two cycles of chemotherapy; ASCT, autologous stem-
cell transplantation; WBRT, whole-brain radiotherapy.
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expression to consider further confounding variables. In 
60 (78.9%) patients who did not undergo upfront ASCT, 
high PD-1 expression was observed in 5 (8.3%) patients 
and they tended to associate with inferior survival (Figure 
3a for OS and Figure 3b for PFS) although not statistically 
significant.
Survival of patients with high PD-1 expression
We further analyzed survival of patients with high 
PD-1 expression to better characterize the patients with 
high PD-1 expression in PCNSL tumor microenvironment. 
The median survival of patients with high PD-1 expression 
was only 15.8 months (95% CI: 11.7–19.9) for OS and 
10.4 months (95% CI: 3.3–17.5) for PFS. However, the 
median OS of patients with low PD-1 expression was 
not reached, and median PFS was 24.7 months (95% 
CI: 9.8–39.5) in patients with low PD-1. All the PCNSL 
patients with high PD-1 expression had DLBCL histology 
and two out of six patients showed positive serum EBV 
DNA among high PD-1 patients. Among six patients with 
high PD-1 expression, three patients achieved CR1 and 
five patients achieved CR after completion of primary 
chemotherapy.
Among these high PD-1 expressing patients, four 
patients died of disease progression, although four of 
whom received WBRT consolidation (median 4.0 [range 
30.6–54.0] Gy) and one patient received upfront ASCT 
consolidation. Among four patients with high PD-1 who 
died of progression, two patients were intermediate-risk, 
one patient was low-risk, and one patient had missing 
data according to the IELSG scoring. Regarding MSKCC 
scoring, two patients belonged to low-risk, and the 
remaining two patients belonged to intermediate and high-
Figure 1: Representative immunohistochemical stains in formalin-fixed and paraffin-embedded samples. Negative 
control (a), high PD-1 expression (b), PD-L1 (c), and PD-L2 (d) with anti-PD-1 antibody (NAT105, a and b), anti-PD-L1 antibody 
(ab58810, c), and anti-PD-L2 antibody (MIH18, d). Magnification, ×400.
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risk, respectively. Additional characteristics of patients 
with high PD-1 expression are provided in Table 5.
Correlation of PD-1 expression with PD-L1 and 
PD-L2 expression levels
The association of PD-1 expression with PD-L1 and 
PD-L2 expression in tumor microenvironment of PCNSL 
is shown in Table 6. The level of PD-1 expression was 
significantly associated with the level of PD-L1 (P = 
0.020) and PD-L2 (P < 0.001), respectively (Table 6).
DISCUSSION
In this study, we found that high 
immunohistochemical PD-1 expression in biopsy 
specimen of patients with PCNSL at diagnosis was 
significantly associated with inferior OS and PFS.
Much information has been accumulated regarding 
the pathogenesis and tumor microenvironment of PCNSL 
[13]. However, in addition to the rarity of the disease, 
obtaining adequate numbers of specimens is difficult 
and thus prognostic roles of studied biomarkers have 
been unclear. Therefore, IELSG or MSKCC scoring 
is thus far considered the best available clinical tool 
for risk-stratifying PCNSL patients [2, 3], although 
biological prognostic markers that also consider the 
tumor microenvironment and that can be used as a 
therapeutic target are needed to improve prognostication 
and survival of patients with PCNSL. Although our 
group recently reported prognostic importance of CD68 
expression in PCNSL microenvironment [6], the major 
limitation was regarding therapeutic implication as it is 
difficult to modulate immune response via CD68 positive 
macrophages in PCNSL tumor microenvironment.
In this regard, PD-1 is an attractive emerging 
therapeutic target because it has been shown to be 
expressed in various cancers as well as in hematologic 
malignancies [14, 15]. Regarding PD-1 expression in 
PCNSL, Berghoff et al. [16] were among the first to 
demonstrate PD-1 and PD-L1 expression in PCNSL. Of 
20 PCNSL patient specimens, 2 (10.0%) showed moderate 
intensity and 1 (5.0%) had high intensity. Besides, Four 
et al. [17] reported expression of high PD-1 (2+) in 6.2% 
of patients with PCNSL. The proportions of high PD-1 
expressing patients are similar to our study, as 7.9% of 
our patients expressed high PD-1. Compared to those 
studies, our study recruited more number of patients who 
were initially homogenously treated with HD-MTX-based 
chemotherapy. We also performed subgroup analysis 
Table 2: Univariate and multivariate analyses for overall survival (OS) and progression-free survival (PFS)
Clinical features
Univariate analysis Multivariate analysis
P for OS P for PFS HR (95% CI) for OS P HR (95% CI) for PFS P
Age >60 years 0.038 0.159
Male gender 0.140 0.707
ECOG PS≥2 0.047 0.353
Elevated LDH 0.209 0.103
Deep brain lesion 0.696 0.361
Elevated CSF protein 0.074 0.064
Positive serum EBV 0.148 0.173
Non-CR1 0.791 0.005
Non-upfront ASCT 0.238 0.040
MSKCC scoring 0.029 0.046 2.56 (1.17-5.64) 0.019 1.56 (1.09-2.45) 0.041
IELSG scoring 0.036 0.487
PD-1 ≥70 cells/HPF 0.018 0.043 4.95 (1.54-15.86) 0.007 2.73 (1.12-6.69) 0.028
PD-L1 ≥100 cells/HPF 0.764 0.793
PD-L2 ≥100 cells/HPF 0.306 0.940
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative 
Oncology Group; PS, performance status; LDH, lactate dehydrogenase; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; 
CR1, complete response after first two cycles of chemotherapy; ASCT, autologous stem-cell transplantation; HPF, high 
power field; MSKCC, Memorial Sloan Kettering Cancer Center; IELSG, International Extranodal Lymphoma Study Group.
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according to the upfront ASCT, as the role of upfront 
ASCT in high-risk patients with PCNSL was emphasized 
[18].
One of our patient with high PD-1 expression 
died of progression even after receiving upfront ASCT. 
Interestingly, the poor prognosis of patients with high 
PD-1 expression was initially indistinguishable using 
the IELSG or MSKCC scoring systems; because among 
four high PD-1 expressing patients who died of disease 
progression, none of them belonged to the high-risk 
group according to IELSG scoring and only one of them 
belonged to the high-risk group regarding MSKCC 
scoring. However, if we knew that high PD-1 expression 
predicted poor survival in PCNSL, we would have been 
able to get more help regarding selection of treatment for 
these high-risk patients.
There were high expressions of PD-L1 and PD-L2 
in 13.2% and 42.1% of our cohort, respectively. Regarding 
PD-L1 expression, our data also showed quite similar rate 
to that of Four et al. [17], as they reported 18.7% patients 
were PD-L1 high. However, these rates are relatively 
low compared to a recent study of PD-L1 expression in 
Figure 2: The overall survival (OS) and progression-free survival (PFS) according to the level of PD-1 expression (a for OS and b for 
PFS), PD-L1 expression (c for OS and d for PFS), and PD-L2 expression (e for OS and f for PFS).
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Table 3: Two-year overall survival of patients according to their PD-1, PD-L1, and PD-L2 expression status
Clinical features, n
Entire cohort Two-year overall survival (%)
(n = 76)
PD-1
P
PD-L1
P
PD-L2
P
Low (n= 70) High (n= 6) Low (n = 66) High (n = 10) Low (n = 44) High (n = 32)
Age
 ≤60 46 88.7 50.0 0.028 84.5 85.7 0.764 88.6 76.0 0.405
 >60 30 66.2 0.0 0.134 61.9 0.0 0.737 66.3 28.6 0.409
Gender
 Male 37 88.0 33.3 0.008 78.2 100.0 0.274 83.3 82.4 0.718
 Female 39 74.0 33.3 0.231 73.9 33.3 0.344 81.5 36.0 0.111
ECOG PS
 <2 41 91.6 40.0 0.004 82.0 100.0 0.377 92.4 66.1 0.070
 ≥2 35 65.9 0.0 0.199 66.2 50.0 0.981 57.9 65.9 0.572
Serum LDH
 Not elevated 42 71.6 40.0 0.162 66.9 66.7 0.754 75.2 50.6 0.243
 Elevated 34 89.9 0.0 0.024 87.5 80.0 0.949 87.7 83.6 0.813
Serum EBV DNA load
 Not detected 60 81.7 50.0 0.143 80.4 71.4 0.086 85.4 67.4 0.248
 Detected 16 77.4 0.0 0.108 58.0 100.0 0.354 64.6 60.0 0.756
Tumor location
 Non-deep lesion 25 77.6 50.0 0.469 70.6 100.0 0.338 77.4 71.4 0.530
 Deep lesion 51 81.4 0.0 0.009 77.9 62.5 0.730 83.1 65.5 0.368
CSF protein
 Not elevated 36 91.8 33.3 0.001 83.5 100.0 0.320 83.3 90.9 0.569
 Elevated 30 64.3 50.0 0.673 72.3 33.3 0.440 76.6 30.3 0.249
 Not available 10 85.7 0.0 0.155 68.6 100.0 0.558 0.0 60.0 0.295
IELSG
 Low (0-1) 12 77.1 50.0 0.426 65.6 100.0 0.377 75.0 66.7 0.743
 Intermediate (2-3) 46 88.9 33.3 0.015 82.4 100.0 0.315 83.2 85.7 0.898
 High (4-5) 8 28.1 N/A N/A 66.7 0.0 0.623 50.0 31.3 0.275
 Missing 10 85.7 0.0 0.155 100.0 68.6 0.558 100.0 60.0 0.295
MSKCC
 Low (1) 15 100.0 0.0 <0.001 84.6 100.0 0.571 100.0 66.7 0.070
 Intermediate (2) 32 83.9 66.7 0.531 77.6 100.0 0.321 81.5 80.0 0.858
 High (3) 29 62.1 0.0 0.333 67.2 0.0 0.235 65.2 33.7 0.468
Initial interim response
 CR1 39 83.6 25.0 0.007 77.6 66.7 0.839 80.8 65.6 0.605
 Non-CR1 37 77.0 50.0 0.474 73.8 75.0 0.896 80.9 64.5 0.282
Upfront ASCT
 Yes 16 100.0 0.0 <0.001 92.3 100.0 0.395 100.0 85.7 0.738
 No 60 74.4 40.0 0.160 53.3 71.8 0.780 76.2 54.5 0.307
Consolidation WBRT
 Yes 12 66.7 50.0 0.707 70.4 0.0 0.089 79.1 0.0 0.021
 No 64 85.4 0.0 <0.001 78.0 100.0 0.159 81.9 80.9 0.962
ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus; CSF, cerebrospinal fluid; IELSG, International 
Extranodal Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; CR1, complete response after first two cycles of chemotherapy; ASCT, autologous 
stem-cell transplantation; WBRT, whole-brain radiotherapy; N/A, not available.
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glioblastoma, which is a completely different disease but 
also the malignant case in the CNS [19].
PD-L1 expression might have been induced by 
genetic aberrations within tumor cells such as Hodgkin 
lymphoma and primary mediastinal large B-cell lymphoma, 
which harbor amplification of 9p24.1, a genomic region 
that encodes PD-L1 and PD-L2. Interestingly, gain of 
9p24.1 was also observed in PCNSL [7]. Indeed, PCNSL is 
associated with immunodeficiency [1], and PCNSL might 
evade the immune system utilizing PD-1 pathway [9], 
resulting in poorer outcome compared to non-CNS disease. 
Our observation suggests a possible link between high 
PD-1 expression and poor survival, which could explain 
the more aggressive behavior associated with high PD-1 
expression. Furthermore, we demonstrated significant 
correlation of PD-1 expression with PD-L1 and PD-L2, 
which is in line with previous studies [17, 20]. Therefore, 
our study might be used as a basis for future clinical trial 
targeting PD-1 pathway in PCNSL.
We acknowledge our limitation as the expression 
of PD-1 and PD-L1/PD-L2 have not been defined in 
specific cell type due to the lack of double staining with 
CD20, CD3 or other markers for macrophages. However, 
expression of PD-1 in tumor infiltrating lymphocytes 
and PD-L1 in tumor cells were distinguished with 
microscopic visualization by two independent experienced 
hematopathologists. Therefore, our claim that high PD-1 
expression in tumor microenvironment of PCNSL is 
associated with poor survival is assuming that high PD-1 
expression on tumor infiltrating lymphocytes in PCNSL 
tumor microenvironment is associated with poor survival 
of patients with PCNSL at diagnosis.
We also estimated PD-1, PD-L1, and PD-L2 
expression visually followed by calculation of the mean 
Table 4: Association of PD-1, PD-L1, and PD-L2 expression with survival
Clinical features Total patients (n)
Deaths 
(n)
Median OS 
(95% CI) P
Progression 
(n)
Median PFS 
(95% CI) P
PD-1, cells/HPF 0.008 0.037
 <70 70 12 Not reached 34 24.7 (9.8-39.5)
 ≥70 6 4 15.8 (11.7-19.9) 6 10.4 (3.3-17.5)
PD-L1, cells/HPF 0.814 0.895
 <100 66 14 Not reached 34 17.9 (6.9-28.8)
 ≥100 10 2 Not reached 6 23.4 (13.1-33.8)
PD-L2, cells/HPF 0.310 0.953
 <100 44 8 Not reached 24 23.4 (12.8-33.9)
 ≥100 32 8 Not reached 16 17.1 (13.9-20.3)
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; HPF, high power field.
Figure 3: The overall survival (OS, a) and progression-free survival (PFS, b) according to the level of PD-1 expression among subgroup 
of patients who did not receive upfront autologous stem-cell transplantation (ASCT).
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number of positive cells/HPF and cut-off values have been 
chosen by AUC of receiver operating characteristic (ROC) 
curve for analytic purposes. However, we acknowledge 
the fundamental limitation to standardize the way of 
determining the optimal cut-off values for PD-1 and its 
ligands expression from tumor biopsy samples is difficult. 
Therefore, the predictive relevance of our method and 
determining optimal cut-off values remain to be validated 
in future studies.
In conclusion, we showed that high PD-1 expression 
in PCNSL tumor microenvironment is significantly 
associated with inferior survival. Better knowledge of 
the PD-1 pathway in PCNSL, along with future trials 
that include PD-1 based biological risk-stratification and 
therapeutic targeting, are necessary for this challenging 
disease.
MATERIALS AND METHODS
Patients
Seventy-six biopsy-proven PCNSL patients 
between December 2004 and March 2016 at Severance 
Hospital, South Korea for whom archived formalin-fixed 
and paraffin-embedded (FFPE) tissue blocks at initial 
diagnosis were available were retrospectively analyzed. 
The patient cohort was previously described [6]. All the 
patients included in this study were immunocompetent 
and did not have a history of immunosuppressive drug 
use nor malignancies other than PCNSL. We excluded 
human immunodeficiency virus-related PCNSL. The 
diagnosis was made histologically by surgical resection 
or stereotactic brain biopsy. All the patients received 
HD-MTX-based chemotherapy as an initial treatment 
homogenously without receiving steroid treatment before 
pathologic confirm.
PCNSL was stipulated as histologically confirmed 
NHL confined to the CNS [1]. Baseline clinical data 
were retrospectively collected including age, gender, 
IELSG prognostic score, MSKCC prognostic score, 
serum EBV positivity by quantitative polymerase chain 
reaction, serum human immunodeficiency virus positivity 
by enzyme immunoassay, type of treatment including 
consolidative upfront ASCT and WBRT, initial response 
to treatment, and survival.
The ECOG performance status was determined at 
the time of diagnosis. Pre-treatment evaluation included 
contrast enhanced magnetic resonance imaging of the brain, 
positron emission tomography-computed tomography 
to exclude systemic NHL, bone marrow aspiration and 
biopsy with histologic, cytologic, and immunocytologic 
examination, ocular examination including a slit lamp 
examination to distinguish ocular involvement, and lumbar 
puncture for cerebrospinal fluid (CSF) analysis, unless 
contraindicated. Elevated CSF protein concentration was 
defined as a level more than 45 mg/dL in patients younger 
than 60 years of age, and a level more than 60 mg/dL in 
patients older than 60 years of age [2]. Involvement of 
deep brain structures was defined as involvement of the 
Table 5: Clinical characteristics of six patients with high PD-1 expression
Age Gender ECOG PS LDH Lesion
CSF 
protein
IELSG 
scoring
MSKCC 
scoring
PD-1, 
cells/
HPF
PD-
L1, 
cells/
HPF
PD-
L2, 
cells/
HPF
Initial 
treatment
Interim 
response
Final response 
after primary 
chemotherapy
Treatment 
after primary 
chemotherapy
OS 
(mon)
PFS 
(mon) COD
1 68 F 2 Elevated Non-deep Normal 3 2 92 10 0 MVP CR1 CR Consolidation WBRT 15.8 10.4 PD
2 34 F 1 Normal Deep Elevated 2 0 132 10 110 MVP CR1 CR Upfront ASCT 8.1 8.1 PD
3 59 F 1 Normal Non-deep Normal 0 1 230 7 5 MVD Non-CR1 CR
Consolidation 
WBRT 34.5 15.2 Censored
4 64 M 1 Normal Deep N/A N/A 1 150 18 200 MVD Non-CR1 CR
Consolidation 
WBRT 17.9 17.9 PD
5 39 M 1 Normal Deep Normal 1 0 240 78 200 MVD Non-CR1 PR
Salvage 
Chemotherapy 14.5 9.3 PD
6 60 M 1 Normal Deep Elevated 2 1 157 5 70 MVD CR1 CR Consolidation WBRT 21.8 16.2 Censored
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; IELSG, International Extranodal 
Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; HPF, high power field; OS, overall survival; PFS, progression-free survival; COD, cause of death; F, Female; M, Male; DLBCL, 
diffuse large B-cell lymphoma; N/A, not available; MVP, methotrexate, vincristine, procarbazine and dexamethasone; MVD, methotrexate, vincristine and dexamethasone; CR1, complete response after 
initial two cycles of chemotherapy; CR, complete response; PR, partial response; ASCT, autologous stem-cell transplantation; WBRT, whole-brain radiotherapy; PD, progressive disease.
Table 6: Correlation of PD-1 expression with PD-L1 and PD-L2
Parameters Correlation coefficient P
PD-L1 0.267 0.020
PD-L2 0.397 <0.001
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periventricular regions, basal ganglia, brainstem, and 
cerebellum.
The IELSG scoring system [2], which consists 
of five prognostic factors that are associated with 
poor survival in PCNSL including age > 60 years, 
ECOG performance status > 1, elevated serum lactate 
dehydrogenase level, elevated CSF protein concentration, 
and involvement of deep brain structures, was assessed 
in 66 (86.8%) patients, as data regarding the CSF protein 
level were not available in 10 (13.2%) patients. The 
MSKCC scoring system [3], consisting of age ≥ 50 and 
Karnofsky performance score (KPS) ≥ 70, which are 
predictors of poor outcome in PCNSL, was evaluated in 
all patients.
All patients included in this study had received HD-
MTX-based chemotherapy as an initial treatment, such 
as HD-MTX, vincristine, and dexamethasone (MVD, n = 
41) or HD-MTX, procarbazine, and dexamethasone (MVP, 
n = 35). The MVD regimen consisted of HD-MTX 3.5 
g/m2 D1 delivered intravenously (i.v.) with leucovorin 
rescue (15 mg every 6 hours, minimum 12 doses), started 
24 hours after the MTX infusion, vincristine 1.4 mg/
m2 (maximum 2 mg i.v.) D1, and dexamethasone 20 
mg i.v. D1-5. The MVP regimen consisted of HD-MTX 
3.0 g/m2 D1 i.v. with leucovorin rescue (15 mg every 
6 hours, minimum 12 doses), started 24 hours after the 
MTX infusion, vincristine 1.4 mg/m2 (maximum 2 mg 
i.v.) D1, procarbazine 100 mg/m2 D1-14 given orally, 
and dexamethasone 20 mg i.v. D1-14. Tumor response 
was assessed according to the criteria of the International 
PCNSL Collaborative Group [21]. Treatment response 
was recorded as complete response1 (CR1), if the 
patients achieved a CR (disappearance of all enhancing 
abnormalities on brain magnetic resonance imaging) after 
initial induction HD-MTX-based chemotherapy. The 
institutional review board of Severance Hospital approved 
this study.
Immunohistochemistry of PD-1, PD-L1, and 
PD-L2
Immunohistochemical staining for PD-1 (clone 
NAT105; dilution 1:100; Abcam, Cambridge, UK), PD-L1 
(clone ab58810; dilution 1:100; Abcam, Cambridge, UK), 
and PD-L2 (clone MIH18; dilution 1:50; Sigma-Aldrich, 
St. Louis, MO, USA) using archived FFPE tissue slides 
were performed according to the protocols for automated 
immunohistochemistry using the Ventana Discovery XT 
automatic platform (Ventana Automated Systems, Tucson, 
AZ, USA).
Quantitative assessment of PD-1, PD-L1, and 
PD-L2
The stained sections were screened at 40× 
magnification via Olympus BX51 microscope (Olympus, 
Deutschland GmbH, Hamburg, Germany; 40× objective, 
10× ocular, and 0.55 mm ocular diameter) to identify 
the areas with the most abundant positive cells within 
the tumor area. Six representative fields with the highest 
staining tumor cells were selected at a magnification 
of 400× HPF. We analyzed 1.44 mm2 per case because 
the area of a single image was 0.24 mm2. PD-1 positive 
tumor-infiltrating mononuclear cells (i.e. lymphocytes 
and macrophages) and PD-L1/PD-L2 positive tumor 
cells were counted manually, and the mean numbers of 
positive cells/HPF were calculated. Blinded quantitative 
assessments were performed by two independent 
pathologists (SHK and W-IY). The cut-off values for 
high PD-1, PD-L1, and PD-L2 were evaluated by the 
AUC of the ROC curve, and we established cut-offs of 
70 cells/HPF for PD-1 and 100 cells/HPF for PD-L1/PD-
L2. Therefore, high PD-1 expression was defined as ≥ 70 
cells/HPF, and high PD-L1/PD-L2 were defined as ≥ 100 
cells/HPF.
Statistical analysis
OS was defined as the time from initial diagnosis to 
death or last follow-up; PFS was defined as the time from 
initial diagnosis to relapse, disease progression, or death. 
Patient data were collected retrospectively until March 
2016, and patients who were alive at the last follow-up 
contact were censored. OS and PFS were plotted using the 
Kaplan-Meier method and compared using the log-rank 
test. Analysis of categorical variables was performed using 
the chi-squared test or Fisher’s exact test. The Wilcoxon 
rank-sum test was used for continuous variables. The 
Cox regression model was used in both univariate and 
multivariate analysis. All P values were two-sided, and P 
< 0.05 was considered statistically significant. Statistical 
analyses were performed using SPSS for Windows 
(Version 20.0, IBM Corp., Chicago, IL, USA).
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